DWM
HRTX icon

Destination Wealth Management’s Heron Therapeutics HRTX Stock Holding History

Destination Wealth Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-2
Closed – – 284
2019
Q2 		$0 Hold
2
– – ﹤0.01% 638
2019
Q1 		$0 Hold
2
– – ﹤0.01% 695
2018
Q4 		$0 Hold
2
– – ﹤0.01% 599
2018
Q3 		$0 Hold
2
– – ﹤0.01% 716
2018
Q2 		$0 Hold
2
– – ﹤0.01% 573
2018
Q1 		$0 Buy
+2
New +$45 ﹤0.01% 575

Other funds holding HRTX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Destination Wealth Management's HRTX Position: Q3 2019 in Review

Destination Wealth Management sold out of Heron Therapeutics (HRTX) in Q3 2019, closing a stake of 2 shares.

Destination Wealth Management first reported a position in HRTX in Q1 2018 and held it in 6 quarters. The position peaked at $0 in Q2 2019. 180 funds tracked by Wall St. Rank hold HRTX as of Q3 2019.

  • Destination Wealth Management reported no remaining Heron Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Destination Wealth Management sold 2 Heron Therapeutics shares in Q3 2019.
  • Destination Wealth Management first reported a position in Heron Therapeutics in Q1 2018 and held it in 6 quarters.
  • Destination Wealth Management's Heron Therapeutics position peaked at $0 in Q2 2019.
  • 180 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2019.

Based on Destination Wealth Management's 13F filing for Q3 2019, filed 13 Nov 2019.